News

Fintel reports that on April 21, 2023, Needham reiterated coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation.

Analyst Price Forecast Suggests 140.49% Upside

As of April 6, 2023, the average one-year price target for KalVista Pharmaceuticals is $19.72. The forecasts range from a low of $14.14 to a high of $25.20. The average price target represents an increase of 140.49% from its latest reported closing price of $8.20.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for KalVista Pharmaceuticals is $0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -$4.13.

What is the Fund Sentiment?

There are 242 funds or institutions reporting positions in KalVista Pharmaceuticals. This is an increase of 10 owner(s) or 4.31% in the last quarter. Average portfolio weight of all funds dedicated to KALV is 0.10%, a decrease of 22.62%. Total shares owned by institutions increased in the last three months by 34.24% to 35,838K shares.

The put/call ratio of KALV is 0.47, indicating a bullish outlook.

What are Other Shareholders Doing?

TCG Crossover Management holds 3,395K shares representing 9.94% ownership of the company.

Frazier Life Sciences Management holds 3,239K shares representing 9.48% ownership of the company. In it's prior filing, the firm reported owning 1,572K shares, representing an increase of 51.46%. The firm decreased its portfolio allocation in KALV by 99.92% over the last quarter.

Tang Capital Management holds 3,196K shares representing 9.35% ownership of the company. In it's prior filing, the firm reported owning 1,800K shares, representing an increase of 43.69%. The firm decreased its portfolio allocation in KALV by 1.99% over the last quarter.

VR Adviser holds 2,917K shares representing 8.54% ownership of the company.

Jefferies Financial Group holds 1,200K shares representing 3.51% ownership of the company.

KalVista Pharmaceuticals Background Information
(This description is provided by the company.)

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with a Phase 2 clinical trial expected to initiate in the second quarter of 2021. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

See all KalVista Pharmaceuticals regulatory filings.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.